<?xml version="1.0" encoding="UTF-8"?><feed xmlns="http://www.w3.org/2005/Atom">
  <title>临床试验招募信息 | wechat-feeds</title>
  <id>https://github.com/hellodword/wechat-feeds</id>
  <updated>2020-11-03T11:12:52+08:00</updated>
  <subtitle>帮您更方便、更快捷的了解正在开展的临床试验招募信息！</subtitle>
  <link href="https://github.com/hellodword/wechat-feeds"></link>
  <author>
    <name>hellodword</name>
  </author>
  <entry>
    <title>【厚德奥科PD-L1招募患者6】LP002治疗复发或难治性原发纵隔大B细胞淋巴瘤患者的多中心、开放性、单臂Ⅱ期研究</title>
    <updated>2020-11-03T07:43:33+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-03:/s/_efwvr7e8zOr8B1VS2Y3eA</id>
    <link href="https://mp.weixin.qq.com/s/_efwvr7e8zOr8B1VS2Y3eA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>【招募患者】评估AK112用于治疗晚期实体瘤的安全性、药代动力学和抗肿瘤活性的开放、多中心、剂量递增和剂量扩展I/II期临床试验</title>
    <updated>2020-11-02T07:41:09+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-02:/s/4-7Qx2uFZXkqWINtFkAUsA</id>
    <link href="https://mp.weixin.qq.com/s/4-7Qx2uFZXkqWINtFkAUsA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>【正大天晴PD-L1招募患者19】TQB2450注射液治疗PD-L1阳性的复发或转移性宫颈癌的单臂、开放、多中心II期临床试验</title>
    <updated>2020-11-01T08:44:37+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-01:/s/WlPdbMRKKJ2RFoYR8nhB9w</id>
    <link href="https://mp.weixin.qq.com/s/WlPdbMRKKJ2RFoYR8nhB9w" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>【翰中PD-1招募9】重组人源化抗PD-1单克隆抗体HX008注射液治疗BCG无应答的高危非肌层浸润膀胱癌的II期临床研究</title>
    <updated>2020-10-31T08:05:34+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-10-31:/s/lvgRnXo9ECWgNjh60MrySw</id>
    <link href="https://mp.weixin.qq.com/s/lvgRnXo9ECWgNjh60MrySw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>【招募患者】在接受卡介苗治疗后复发携带FGFR突变或融合的膀胱癌中，比较Erdafitinib和膀胱内化疗药物的随机化II期研究</title>
    <updated>2020-10-30T08:10:58+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-10-30:/s/9wtY01B0deOWcXqBfHvsbw</id>
    <link href="https://mp.weixin.qq.com/s/9wtY01B0deOWcXqBfHvsbw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>【招募患者】注射用醋酸地加瑞克在前列腺癌患者中的多中心、随机、开放、两序列、单次给药的人体生物等效性临床研究</title>
    <updated>2020-10-29T08:54:40+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-10-29:/s/jvmxjzScolqreEth30HJvw</id>
    <link href="https://mp.weixin.qq.com/s/jvmxjzScolqreEth30HJvw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>【招募患者】评价HMPL-689治疗标准治疗失败或无标准治疗的淋巴瘤患者的安全性、药代动力学及初步疗效的I期开放性研究</title>
    <updated>2020-10-27T09:49:46+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-10-27:/s/DINOqXlubelKLYSjEDJ-vQ</id>
    <link href="https://mp.weixin.qq.com/s/DINOqXlubelKLYSjEDJ-vQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>【招募患者】评估抗 Trop2 单抗-Tub196 偶联剂在晚期实体瘤中的安全性、PK特征的开放、剂量递增 I 期临床研究</title>
    <updated>2020-10-26T07:47:42+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-10-26:/s/YteY8BaOw7YVYgaBwo2PEA</id>
    <link href="https://mp.weixin.qq.com/s/YteY8BaOw7YVYgaBwo2PEA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>【招募患者】甲磺酸阿美替尼联合化疗作为可完全切除的EGFR突变非小细胞肺癌围手术期治疗的随机、对照、双盲、多中心III期临床研究</title>
    <updated>2020-10-25T09:10:41+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-10-25:/s/zuP6PWIHQA6alSpvVXOWkw</id>
    <link href="https://mp.weixin.qq.com/s/zuP6PWIHQA6alSpvVXOWkw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>【招募患者】ST-1898片在晚期实体瘤患者中的安全性、耐受性、药代动力学和初步疗效的I期临床试验</title>
    <updated>2020-10-24T09:17:59+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-10-24:/s/chw3PzuyznYRYEoqxOXvYw</id>
    <link href="https://mp.weixin.qq.com/s/chw3PzuyznYRYEoqxOXvYw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
</feed>